Literature DB >> 29404400

miRNA displacement as a promising approach for cancer therapy.

David Gilot1,2,3, Marie-Dominique Galibert1,2,3,4.   

Abstract

microRNA (miRNA) are critical post-transcriptional regulators and key players in diseases development. We demonstrated that non-canonical microRNA Responsive Elements (here MRE-16) could sequester miR-16, dampening miR-16 tumor suppressor function. We developed small oligonucleotides, masking specifically these unusual miR-16 binding sites, that restored miR-16 function. This constitutes a promising targeted approach.

Entities:  

Keywords:  TYRP1; antisense oligonucleotides; melanoma; miRNA

Year:  2017        PMID： 29404400      PMCID： PMC5791856          DOI： 10.1080/23723556.2017.1406432

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Genome-scale RNAi profiling of cell division in human tissue culture cells.

Authors:  Ralf Kittler; Laurence Pelletier; Anne-Kristine Heninger; Mikolaj Slabicki; Mirko Theis; Lukasz Miroslaw; Ina Poser; Steffen Lawo; Hannes Grabner; Karol Kozak; Jan Wagner; Vineeth Surendranath; Constance Richter; Wayne Bowen; Aimee L Jackson; Bianca Habermann; Anthony A Hyman; Frank Buchholz
Journal:  Nat Cell Biol       Date:  2007-11-11       Impact factor: 28.824

Review 2.  The chemical evolution of oligonucleotide therapies of clinical utility.

Authors:  Anastasia Khvorova; Jonathan K Watts
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

Review 3.  Definition and identification of small RNA sponges: Focus on miRNA sequestration.

Authors:  Mélodie Migault; Emmanuelle Donnou-Fournet; Marie-Dominique Galibert; David Gilot
Journal:  Methods       Date:  2016-11-19       Impact factor: 3.608

Review 4.  FDA-Approved Oligonucleotide Therapies in 2017.

Authors:  Cy A Stein; Daniela Castanotto
Journal:  Mol Ther       Date:  2017-03-31       Impact factor: 11.454

Review 5.  Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma.

Authors:  Ghanem Ghanem; Journé Fabrice
Journal:  Mol Oncol       Date:  2011-02-03       Impact factor: 6.603

6.  A non-coding function of TYRP1 mRNA promotes melanoma growth.

Authors:  David Gilot; Mélodie Migault; Laura Bachelot; Fabrice Journé; Aljosja Rogiers; Emmanuelle Donnou-Fournet; Ariane Mogha; Nicolas Mouchet; Marie-Laure Pinel-Marie; Bernard Mari; Tristan Montier; Sébastien Corre; Arthur Gautron; Florian Rambow; Petra El Hajj; Rania Ben Jouira; Sophie Tartare-Deckert; Jean-Christophe Marine; Brice Felden; Ghanem Ghanem; Marie-Dominique Galibert
Journal:  Nat Cell Biol       Date:  2017-10-09       Impact factor: 28.824

7.  Melanoma addiction to the long non-coding RNA SAMMSON.

Authors:  Eleonora Leucci; Roberto Vendramin; Marco Spinazzi; Patrick Laurette; Mark Fiers; Jasper Wouters; Enrico Radaelli; Sven Eyckerman; Carina Leonelli; Katrien Vanderheyden; Aljosja Rogiers; Els Hermans; Pieter Baatsen; Stein Aerts; Frederic Amant; Stefan Van Aelst; Joost van den Oord; Bart de Strooper; Irwin Davidson; Denis L J Lafontaine; Kris Gevaert; Jo Vandesompele; Pieter Mestdagh; Jean-Christophe Marine
Journal:  Nature       Date:  2016-03-24       Impact factor: 49.962

8.  The effect of antisense tyrosinase-related protein 1 on melanocytes and malignant melanoma cells.

Authors:  C-Y Li; T-W Gao; G Wang; Z-Y Han; Z Shen; T-H Li; Y-F Liu
Journal:  Br J Dermatol       Date:  2004-06       Impact factor: 9.302

9.  TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome.

Authors:  F Journe; H Id Boufker; L Van Kempen; M-D Galibert; M Wiedig; F Salès; A Theunis; D Nonclercq; A Frau; G Laurent; A Awada; G Ghanem
Journal:  Br J Cancer       Date:  2011-11-01       Impact factor: 7.640

10.  SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma.

Authors:  P El Hajj; D Gilot; M Migault; A Theunis; L C van Kempen; F Salés; H Fayyad-Kazan; B Badran; D Larsimont; A Awada; L Bachelot; M-D Galibert; G Ghanem; F Journe
Journal:  Br J Cancer       Date:  2015-06-11       Impact factor: 7.640
  10 in total
  2 in total

1.  MicroRNA-126 exerts antitumor functions in ovarian cancer by targeting EGFL7 and affecting epithelial-to-mesenchymal transition and ERK/MAPK signaling pathway.

Authors:  Yuhua Zhang; Xiaobo Qin; Juan Jiang; Wenjie Zhao
Journal:  Oncol Lett       Date:  2020-05-29       Impact factor: 2.967

2.  Circular RNA Complement Factor H (CFH) Promotes Glioma Progression by Sponging miR-149 and Regulating AKT1.

Authors:  Aimiao Bian; Yanping Wang; Ji Liu; Xiaodong Wang; Dai Liu; Jian Jiang; Lianshu Ding; Xiaobo Hui
Journal:  Med Sci Monit       Date:  2018-08-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.